US 12,186,304 B2
Method for treating cancer by combination of IAP inhibitor and modulator of immune checkpoint molecule
Dajun Yang, Suzhou (CN); Yifan Zhai, Suzhou (CN); Douglas Dong Fang, Suzhou (CN); Guangfeng Wang, Suzhou (CN); Qiuqiong Tang, Suzhou (CN); Wentao Pan, Suzhou (CN); and Jiao Ji, Suzhou (CN)
Assigned to Ascentage Pharma (Suzhou) Co., LTD., Jiangsu (CN)
Appl. No. 16/618,792
Filed by ASCENTAGE PHARMA (SUZHOU) CO., LTD., Suzhou (CN)
PCT Filed Jul. 30, 2019, PCT No. PCT/CN2019/098331
§ 371(c)(1), (2) Date Dec. 2, 2019,
PCT Pub. No. WO2020/024932, PCT Pub. Date Feb. 6, 2020.
Claims priority of application No. 201810859866.6 (CN), filed on Jul. 31, 2018; application No. PCT/CN2019/074791 (WO), filed on Feb. 11, 2019; application No. PCT/CN2019/088527 (WO), filed on May 27, 2019; and application No. 201910575352.2 (CN), filed on Jun. 28, 2019.
Prior Publication US 2021/0330642 A1, Oct. 28, 2021
Int. Cl. A61K 31/407 (2006.01); A61K 9/00 (2006.01); A61K 31/337 (2006.01); A61K 31/5517 (2006.01); A61K 31/555 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01)
CPC A61K 31/407 (2013.01) [A61K 9/0019 (2013.01); A61K 31/337 (2013.01); A61K 31/5517 (2013.01); A61K 31/555 (2013.01); A61P 35/00 (2018.01); C07K 16/2818 (2013.01); A61K 2039/505 (2013.01); A61K 2039/545 (2013.01)] 22 Claims
 
1. A method for treating cancer, suppressing_cancer, reducing the severity of cancer, lowering the risk of cancer, or inhibiting the metastasis of cancer in an individual, the method comprising administering to the individual a therapeutically effective amount of an IAP inhibitor, a therapeutically effective amount of a modulator of an immune checkpoint molecule, and a therapeutically effective amount of a tubulin inhibitor;
wherein the IAP inhibitor is APG-1387, the modulator of an immune checkpoint molecule is anti-PD-1 antibody, and the tubulin inhibitor is docetaxel or paclitaxel.